Nukatsuka M, Fujioka A, Saito H, Nakano K, Uchida J, Oh-ie S, Nomura N, Takeda S, Unemi N, Ishitani K
Anticancer and Antimicrobials Research LAB., Taiho Pharmaceutical Co., LTD.
Gan To Kagaku Ryoho. 1994 Sep;21(12):2013-20.
We established a cancer cachexia model in BALB/c mice bearing Colon 26 and examined antitumor and anticachectic activity of UFT. The mice bearing Colon 26 showed a progressive loss of body weight, loss of lipid, and hypalbuminosis associated with the change of tumor size and these symptoms were improved by removal of cancer. In this model UFT extended life span significantly at 15mg/kg/day though showed a little growth inhibitory activity. UFT showed a significant tumor growth inhibitory activity and extended life span at 20mg/kg/day and could reverse all biological parameters mentioned above. Since the intratumor and plasma contents of IL-6 were significantly lowered in the UFT administered group, it is estimated that the anticachectic activity of UFT originates from reduction of interleukin-6 in tumor.
我们在荷Colon 26结肠癌的BALB/c小鼠中建立了癌症恶病质模型，并检测了优福定（UFT）的抗肿瘤和抗恶病质活性。荷Colon 26结肠癌的小鼠出现体重逐渐减轻、脂质丢失和低白蛋白血症，这些症状与肿瘤大小的变化相关，且通过切除肿瘤可得到改善。在该模型中，优福定以15mg/kg/天的剂量显著延长了小鼠的寿命，尽管其生长抑制活性较弱。优福定以20mg/kg/天的剂量显示出显著的肿瘤生长抑制活性并延长了寿命，且能逆转上述所有生物学参数。由于优福定给药组肿瘤内和血浆中的白细胞介素-6含量显著降低，据推测优福定的抗恶病质活性源于肿瘤中白细胞介素-6的减少。
